Morristown, NJ, United States
Morristown, NJ, United States

Time filter

Source Type

Turner T.J.,Vicus Therapeutics | Bascomb N.,Vicus Therapeutics | Maki J.,Vicus Therapeutics | Rao N.,Vicus Therapeutics | Young F.S.,Vicus Therapeutics
Drug Discovery Today: Therapeutic Strategies | Year: 2012

We define 'orphaned drugs' as those proven drugs that have been abandoned because of a perceived inability to develop them commercially for new indications. Using a hierarchical-network ('HiNET') algorithm applied to a disease of interest,we identify the probable drug candidates for repurposing based on the similarity principle. Here, we describe an approach for selection and commercial development of multidrug regimens using innovative analytical and business models. © 2011 Elsevier Ltd. All rights reserved.


Patent
Vicus Therapeutics | Date: 2015-08-31

The invention provides preparations, formulations, kits and other products of manufacture (e.g., blister packs) comprising combinations of beneficial ingredients that are serviceable as therapies for improving states and disease symptoms such as involving inflammation, excessive sympathoneural drive, cachexia, anorexia, and anorexia-cachexia, as well as stress or anxiety related thereto, and methods of making and using them. The invention provides compositions and therapies comprising use of a beta adrenergic antagonist (also called beta blockers, e.g., propranolol) in combination with an anti-inflammatory agent, e.g., a nonsteroidal anti-inflammatory drug (NSAID), an angiotensin-converting enzyme (ACE) inhibitor, an angiotensin receptor blocker (ARB), an anabolic steroid, a natural oil or fatty acid or any combination thereof.


In alternative embodiments the invention provides compositions, e.g., pharmaceutical compositions and preparations, formulations, kits and other products of manufacture, e.g., exemplary drug combinations packaged together or separately in blister packs, lidded blisters or blister cards, or wrapped in paper, plastic or cellophane wrappers (e.g., a shrink wrap), comprising a combination regimen of at least two active ingredients designed to diminish systemic inflammation by targeting (inhibiting) two different, but convergent, signaling pathways, i.e., the sympathetic nervous system and the lipid-derived autacoid system; and methods for making and using these compositions. In alternative embodiments, the compositions of the invention (e.g., the combination of drugs) are used to ameliorate, diminish, treat, block or prevent an inflammatory response secondary to an infection, e.g., a viral infection and/or a reactivation.


Patent
Vicus Therapeutics | Date: 2016-06-08

In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any condition caused by dysfunctional cells, e.g., mucositis therapies (e.g., for oral mucositis; digestive mucositis; esophageal mucositis; intestinal mucositis). In alternative embodiments, the invention provides cytoprotection products that may be used either alone or in combination with other medical therapies such as cancer chemotherapies and radiation therapies.


The invention provides a therapeutic combination for use in the treatment of cachexia or of a maladaptive nutritional state secondary to a chronic Systemic Inflammatory Response State (SIRS), wherein the combination comprises at least one member of a first group and at least one member of a second group;wherein members of the first group are selected from the group consisting of angiotensin receptor blockers (ARBs); andmembers of the second group are selected from the group consisting of non-steroidal anti-inflammatory drugs (NSAIDs).


Patent
Vicus Therapeutics | Date: 2015-10-06

In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any condition caused by dysfunctional cells, e.g., mucositis therapies (e.g., for oral mucositis; digestive mucositis; esophageal mucositis; intestinal mucositis). In alternative embodiments, the invention provides cytoprotection products that may be used either alone or in combination with other medical therapies such as cancer chemotherapies and radiation therapies.


The invention provides a therapeutic combination for use in the treatment of cachexia or of a maladaptive nutritional state secondary to a chronic Systemic Inflammatory Response State (SIRS), wherein the combination comprises at least one member of a first group and at least one member of a second group;wherein members of the first group are selected from the group consisting of angiotensin-converting enzyme (ACE) inhibitors; andmembers of the second group are selected from the group consisting of non-steroidal anti-inflammatory drugs (NSAIDs).


Patent
Vicus Therapeutics | Date: 2015-10-07

In alternative embodiments, this invention provides compositions and methods for treating cancer or any condition caused by dysfunctional cells, side effects from treatments for cancer or any condition caused by dysfunctional cells, e.g., mucositis therapies (e.g., for oral mucositis; digestive mucositis; esophageal mucositis; intestinal mucositis). In alternative embodiments, the invention provides cytoprotection products that may be used either alone or in combination with other medical therapies such as cancer chemotherapies and radiation therapies.


Loading Vicus Therapeutics collaborators
Loading Vicus Therapeutics collaborators